Astrazeneca Pharma India Ltd (ASTRAZEN)
₹6,889.00
Mkt cap
₹17,360 Cr
P/E ratio
100.00
P/B
19.74
Div yield
0.52%
ROE
23.30%
ROCE
29.30%
EPS (TTM)
₹68.89
Book value
₹349
52W range
6,868–9,828
Sector
Healthcare
Price history
Previous close
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. [1]
NSE ASTRAZENBSE 506820
Health check
Cautious
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−29.90% from high₹6,889
₹6,868+0.31% from low₹9,828
Current
₹6,889.00
Prev close
₹6,950.00
Day
−0.88%
Price performance
1D
−0.88%
1W
−0.90%
1M
−15.90%
3M
−18.50%
6M
−20.83%
1Y
−21.39%
YTD
−19.91%
Financials
Revenue, profit & margin
P/E ratio
100.0×
ASTRAZEN is 194% above the sector median of 34.0×
ASTRAZEN100.0×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 295 | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 | |
| Expenses | 228 | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 | 518 | 634 | |
| Operating Profit | 67 | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 | 75 | 45 | 61 | 49 | |
| OPM % | 23% | 17% | 4.9% | 13% | 10% | 13% | 17% | 18% | 15% | 13% | 7% | 11% | 7% | |
| Other Income | 8 | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 | 1 | 7 | 5 | 9 | |
| Interest | 0 | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 | 4 | 6 | 5 | |
| Profit before tax | 71 | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 | 73 | 47 | 58 | 51 | |
| Tax % | 25% | 29% | 23% | 27% | -22% | 25% | 27% | 26% | 25% | 26% | 30% | 23% | 25% | |
| Net Profit | 54 | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 | |
| EPS in Rs | 21.54 | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 | 13.04 | 17.95 | 15.17 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.55% · closed higher next day 16 of last 59
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Nov '23◦ | 8 Feb '24◦ | 28 May '24 | 8 Aug '24◦ | 14 Nov '24 | 11 Feb '25◦ | 30 May '25◦ | 14 Aug '25 | 7 Nov '25◦ | 11 Feb '26◦ | 26 May '26◦ | 11 Aug '26 |
| Earnings day | −5.29% | −12.90% | +0.47% | +1.24% | −4.99% | +0.68% | +17.12% | −1.21% | +0.06% | −2.69% | −3.51% | −1.77% |
| +1 day | −5.73% | −17.14% | −0.94% | −1.32% | −10.00% | −0.71% | +17.12% | −0.02% | +0.80% | −1.64% | −3.69% | −2.27% |
| +5 days | −5.27% | −16.24% | −12.33% | +0.04% | −9.42% | −6.51% | +26.15% | +0.20% | +0.69% | −1.82% | −5.00% | −5.50% |
| +15 days | −1.63% | −17.06% | −0.83% | +1.29% | −6.86% | +0.25% | +11.34% | +7.47% | −0.12% | −4.01% | −4.84% | −14.50% |
| +30 days | +13.25% | −22.64% | +4.98% | +1.89% | +2.48% | +15.57% | +15.21% | +5.64% | +0.63% | −14.36% | −9.43% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 36 Per Share | 36.00 | 31 Jul '26 | 31 Jul '26 |
Shareholding
as of Jun 202675.00%Promoter
Promoters75.00%
FIIs2.68%0.10
DIIs6.08%0.29
Public16.24%0.18
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| ASTRAZEN | ₹6,944.00 | 100.07 | 17,360 | 0.52% | 38 | −32.04% | 683 | +29.73% | 29.26% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2013nse
Concall transcripts16
Announcements5
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Disclosure Of ESG Rating 2 Sep - Crisil ESG Ratings assigned AstraZeneca Pharma India an ESG score of 64 for FY2026.Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 25 Aug - Delhi High Court stayed NPPA overcharging demand on Betaloc-50 until February 10, 2027, with 15% deposit.Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Disclosure Of ESG Rating 24 Aug - Crisil ESG Ratings assigned AstraZeneca Pharma India an ESG score of 57 on August 24, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 21 Aug - One-on-one virtual institutional investor meeting scheduled for August 26, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15 Aug - Please find the enclosed intimation of the Company as per the captioned subject for your reference.